keyword
MENU ▼
Read by QxMD icon Read
search

prolactin antipsychotic

keyword
https://www.readbyqxmd.com/read/27866695/does-formulation-matter-a-systematic-review-and-meta-analysis-of-oral-versus-long-acting-antipsychotic-studies
#1
REVIEW
Giovanni Ostuzzi, Irene Bighelli, Ryuhei So, Toshi A Furukawa, Corrado Barbui
Recently, many authors highlighted the potential advantages of a broader prescription of long-acting injectable antipsychotics (LAIs) based on various assumptions, including favorable pharmacokinetic features. In this systematic review, data from randomized controlled trials comparing LAIs versus the oral formulation of the same antipsychotic were meta-analyzed in order to ascertain whether the route of administration may be associated with a different efficacy and tolerability profile. Of 21 included studies, 18 contributed to the meta-analysis, providing data for risperidone, olanzapine, aripiprazole, zuclopenthixol, fluphenazine and haloperidol...
November 17, 2016: Schizophrenia Research
https://www.readbyqxmd.com/read/27825323/prolactin-related-adverse-events-and-change-in-prolactin-levels-in-pediatric-patients-given-antipsychotics-for-schizophrenia-and-schizophrenia-spectrum-disorders-a-systematic-review
#2
Eric Druyts, Michael J Zoratti, Kabirraaj Toor, Ping Wu, Salmaan Kanji, Kiran Rabheru, Edward J Mills, Kristian Thorlund
BACKGROUND: Second-generation antipsychotics are commonly prescribed for pediatric patients with schizophrenia and schizophrenia spectrum disorders despite their lack of approval for use in children. Although considered a safer alternative to first-generation antipsychotics, there is evidence to suggest that second-generation antipsychotics may be associated with some adverse events as well as an increase in prolactin levels. The purpose of this review is to examine the risk of prolactin-related adverse events in pediatric patients using antipsychotics and to quantify changes in prolactin for this population...
November 9, 2016: BMC Pediatrics
https://www.readbyqxmd.com/read/27823949/risk-of-breast-cancer-in-risperidone-users-a-nationwide-cohort-study
#3
Johan Reutfors, Louise Wingård, Lena Brandt, Yiting Wang, Hong Qiu, Helle Kieler, Shahram Bahmanyar
BACKGROUND: Several antipsychotics, especially risperidone, are known to increase serum prolactin. Hyperprolactinemia has been linked to the development of mammary gland tumors in animal studies. We therefore investigated the risk of breast cancer in a nationwide cohort of women using risperidone or other antipsychotics. METHODS: All women, 18years or older, who initiated treatment with risperidone or any other antipsychotic between 2006 and 2012 were identified in Swedish nationwide registers...
November 4, 2016: Schizophrenia Research
https://www.readbyqxmd.com/read/27807604/safety-and-tolerability-of-cariprazine-in-the-long-term-treatment-of-schizophrenia-results-from-a-48-week-single-arm-open-label-extension-study
#4
Suresh Durgam, William M Greenberg, Dayong Li, Kaifeng Lu, Istvan Laszlovszky, Gyorgy Nemeth, Raffaele Migliore, Stephen Volk
RATIONALE: Cariprazine, a dopamine D3/D2 receptor partial agonist antipsychotic, demonstrated efficacy and tolerability in 6-week, randomized, placebo-controlled schizophrenia trials. Schizophrenia is a chronic disorder that requires continuous treatment; therefore, the long-term safety and tolerability profile of antipsychotic agents is an important factor in guiding clinician decisions. OBJECTIVE: This single-arm, open-label extension study evaluated the long-term safety and tolerability of cariprazine in patients with schizophrenia...
November 2, 2016: Psychopharmacology
https://www.readbyqxmd.com/read/27800283/prolactin-levels-after-switching-to-paliperidone-palmitate-in-patients-with-schizophrenia
#5
Masaru Nakamura, Takahiko Nagamine, Goro Sato, Kazue Besho
Objective: The aim of this study was to investigate the tolerability and efficacy of paliperidone palmitate and its effect on the levels of prolactin in patients with schizophrenia. Method: A prospective study was carried out in 22 Japanese middle-aged patients with schizophrenia who were switched from paliperidone-extended release or risperidone long-acting injectable to paliperidone palmitate for a minimum of 12 months. Psychotic symptoms using the 18-item Brief Psychiatric Rating Scale, extrapyramidal symptoms using 9-item Drug-induced Extrapyramidal Symptoms Scale, and plasma prolactin levels using fasting blood samples were assessed at Baseline, and one, three, six, and 12 months...
May 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27776952/prolactin-gene-polymorphism-1149-g-t-is-associated-with-hyperprolactinemia-in-patients-with-schizophrenia-treated-with-antipsychotics
#6
Svetlana A Ivanova, Diana Z Osmanova, Anastasia S Boiko, Ivan V Pozhidaev, Maxim B Freidin, Olga Yu Fedorenko, Arkadiy V Semke, Nikolay A Bokhan, Elena G Kornetova, Lubov D Rakhmazova, Bob Wilffert, Anton J M Loonen
BACKGROUND: Antipsychotic drugs can cause hyperprolactinemia. However, hyperprolactinemia was also observed in treatment-naive patients with a first schizophrenic episode. This phenomenon might be related to the role of prolactin as a cytokine in autoimmune diseases. Extrapituitary prolactin production is regulated by an alternative promoter, which contains the functional single nucleotide polymorphism -1149 G/T (rs1341239). We examined whether this polymorphism was associated with hyperprolactinemia in patients with schizophrenia...
October 21, 2016: Schizophrenia Research
https://www.readbyqxmd.com/read/27755159/peony-glycyrrhiza-decoction-for-antipsychotic-related-hyperprolactinemia-in-women-with-schizophrenia-a-randomized-controlled-trial
#7
Sui Cheung Man, Xian-Bin Li, Huai-Hai Wang, Hai-Ning Yuan, Hua-Ning Wang, Rui-Guo Zhang, Qing-Rong Tan, Hei Kiu Wong, Grainne M McAlonan, Chuan-Yue Wang, Zhang-Jin Zhang
OBJECTIVES: An herbal preparation called peony-glycyrrhiza decoction (PGD) may have the potential in reducing antipsychotic-related hyperprolactinemia (hyperPRL). This double-blind, randomized placebo-controlled study aimed to reevaluate the efficacy of PGD against antipsychotic-related hyperPRL. METHODS: Ninety-nine schizophrenic women who were under antipsychotic therapy and had symptomatic hyperPRL were randomly assigned to additional treatment with placebo (n = 50) or PGD (n = 49, 45 g/d) for 16 weeks...
December 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27732772/the-use-of-long-acting-injectable-antipsychotics-in-schizophrenia-evaluating-the-evidence
#8
Christoph U Correll, Leslie Citrome, Peter M Haddad, John Lauriello, Mark Olfson, Stephen M Calloway, John M Kane
Long-acting injectable antipsychotics (LAIs) are among the most effective treatments in psychiatry, yet they remain underutilized in clinical practice. Although LAIs are typically used to maintain treatment adherence in patients with chronic schizophrenia, recent research has suggested that they may also provide an effective treatment strategy for patients with early-phase or first-episode disease. In October 2015, a group of 8 experts on the management of schizophrenia and LAIs met to evaluate the evidence surrounding the efficacy, safety, and cost-effectiveness of LAIs and to develop practical recommendations regarding the clinical use, education, and unmet needs related to LAIs...
2016: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/27672485/brexpiprazole-a-new-treatment-option-for-schizophrenia
#9
REVIEW
Jonathan R Scarff
Schizophrenia occurs in approximately 0.3 to 0.7 percent of the world's population and is associated with significant morbidity and mortality. Although atypical antipsychotics reduce positive and negative symptoms, they are associated with varying degrees of metabolic adverse effects. This necessitates continued development of efficacious yet metabolically favorable treatments. This article reviews brexpiprazole, a medication recently approved to treat patients with schizophrenia. Brexpiprazole was well-tolerated, and adverse reactions were statistically insignificant...
July 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27658834/the-effect-of-antipsychotics-on-bone-mineral-density-and-sex-hormones-in-male-patients-with-schizophrenia
#10
Süheyla Doğan Bulut, Serdar Bulut, Dicle Görkem Atalan, Rıza Gökçer Tulaci, Türker Türker, Eda Gürçay, Çiğdem Aydemir
BACKGROUND: The aim of this study was to compare the bone mineral density (BMD) of male schizophrenia patients with those of healthy controls in order to determine the relationship between BMD and hormonal changes. SUBJECTS AND METHODS: The study sample included male outpatients between 18 and 55 years old, diagnosed with schizophrenia who had used prolactin-raising antipsychotics (n=23) and prolactin-sparing antipsychotics (n=19) for at least twelve months, along with an age - matched healthy control group...
September 2016: Psychiatria Danubina
https://www.readbyqxmd.com/read/27658833/antipsychotic-treatment-prolactin-and-breast-tumorigenesis
#11
Marc De Hert, Davy Vancampfort, Brendon Stubbs, Tine Sabbe, Hans Wildiers, Johan Detraux
BACKGROUND: Over the last decades prolactin (PRL) has gained attention for its possible role in breast tumorigenesis. As all antipsychotics (although differences with respect to PRL elevation are large) have the propensity to induce hyperprolactinemia (HPRL), questions have arisen concerning the influence of PRL-elevating antipsychotic medications on breast cancer risk. SUBJECTS AND METHODS: A literature search (until January 2016), using the MEDLINE database, was conducted for English-language published clinical studies to identify and synthesize data of the current state of knowledge concerning the relationship between HPRL, breast cancer risk (factors) and antipsychotic medication...
September 2016: Psychiatria Danubina
https://www.readbyqxmd.com/read/27639886/-prolactin-antipsychotics-and-breast-cancer-is-there-a-connection
#12
T Sabbe, J Detraux, M De Hert
BACKGROUND: The use of antipsychotics can result in elevated prolactin levels or hyperprolactinemia. An increasing number of studies suggests that prolactin plays a role in mammary carcinogenesis, leading to concerns about a possible relationship between antipsychotics and breast cancer.<br/> AIM: To provide an overview of recent literature regarding the relationship between prolactin, antipsychotics and breast cancer and an association between schizophrenia and breast cancer...
2016: Tijdschrift Voor Psychiatrie
https://www.readbyqxmd.com/read/27629292/once-monthly-paliperidone-palmitate-compared-with-conventional-and-atypical-daily-oral-antipsychotic-treatment-in-patients-with-schizophrenia
#13
Edward Kim, Christoph U Correll, Lian Mao, H Lynn Starr, Larry Alphs
OBJECTIVE: This analysis of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study (NCT01157351) compared outcomes after administration of once-monthly paliperidone palmitate (PP) vs conventional oral antipsychotics (COAs) or atypical oral antipsychotics (AOAs). METHODS: PRIDE was a 15-month study of 444 individuals with schizophrenia and a history of incarceration. They were randomly assigned to PP or to 1 of 7 commonly prescribed OAs...
September 15, 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27574838/effect-of-aripiprazole-lauroxil-on-metabolic-and-endocrine-profiles-and-related-safety-considerations-among-patients-with-acute-schizophrenia
#14
Henry A Nasrallah, John W Newcomer, Robert Risinger, Yangchun Du, Jacqueline Zummo, Anjana Bose, Srdjan Stankovic, Bernard L Silverman, Elliot W Ehrich
OBJECTIVE: Aripiprazole lauroxil, a long-acting injectable antipsychotic, demonstrated safety and efficacy in treating symptoms of schizophrenia in a double-blind, placebo-controlled trial. Because the metabolic profile of antipsychotics is an important safety feature, the effects of aripiprazole lauroxil on body weight, endocrine and metabolic profiles, and safety were examined in a secondary analysis. METHODS: Patients with schizophrenia (DSM-IV-TR criteria) were randomly assigned to aripiprazole lauroxil 441 mg, aripiprazole lauroxil 882 mg, or placebo intramuscularly once monthly between December 2011 and March 2014...
August 30, 2016: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/27553839/current-data-on-and-clinical-insights-into-the-treatment-of-first-episode-nonaffective-psychosis-a-comprehensive-review
#15
REVIEW
Benedicto Crespo-Facorro, Jose Maria Pelayo-Teran, Jacqueline Mayoral-van Son
Implementing the most suitable treatment strategies and making appropriate clinical decisions about individuals with a first episode of psychosis (FEP) is a complex and crucial task, with relevant impact in illness outcome. Treatment approaches in the early stages should go beyond choosing the right antipsychotic drug and should also address tractable factors influencing the risk of relapse. Effectiveness and likely metabolic and endocrine disturbances differ among second-generation antipsychotics (SGAs) and should guide the choice of the first-line treatment...
December 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27550371/tolerability-and-safety-profile-of-cariprazine-in-treating-psychotic-disorders-bipolar-disorder-and-major-depressive-disorder-a-systematic-review-with-meta-analysis-of-randomized-controlled-trials
#16
Kim S J Lao, Ying He, Ian C K Wong, Frank M C Besag, Esther W Chan
BACKGROUND: Cariprazine is a novel antipsychotic agent recently approved for treating schizophrenia and bipolar mania in the USA. The sample sizes of published randomized controlled trials (RCTs) of the drug are small; previous meta-analyses included few RCTs and did not specifically investigate the tolerability/safety profile of cariprazine. OBJECTIVE: Our objective was to conduct a meta-analysis of published RCTs to systematically review the tolerability and safety of cariprazine versus placebo...
August 22, 2016: CNS Drugs
https://www.readbyqxmd.com/read/27499361/safety-and-tolerability-of-long-acting-injectable-versus-oral-antipsychotics-a-meta-analysis-of-randomized-controlled-studies-comparing-the-same-antipsychotics
#17
Fuminari Misawa, Taishiro Kishimoto, Katsuhiko Hagi, John M Kane, Christoph U Correll
OBJECTIVE: We aimed to assess whether long-acting injectable antipsychotics (LAIs), which are initiated in a loading strategy or overlapping with oral antipsychotics (OAPs) and which cannot be stopped immediately, are associated with greater safety/tolerability issues than OAPs. METHOD: Systematic review and meta-analysis of randomized controlled trials (RCTs) comparing LAIs and OAPs, including only LAI-OAP pairs of the same OAP (allowing oral risperidone and paliperidone as comparators for either risperidone or paliperidone LAI)...
October 2016: Schizophrenia Research
https://www.readbyqxmd.com/read/27489377/effects-of-antipsychotics-on-bone-mineral-density-in-patients-with-schizophrenia-gender-differences
#18
REVIEW
Chien-Yu Chen, Hsien-Yuan Lane, Chieh-Hsin Lin
Low bone mineral density (BMD) and osteoporosis are common in patients with schizophrenia and detrimental to illness prognosis and life quality. Although the pathogenesis is not fully clear, series of studies have revealed factors related to low BMD such as life style, psychotic symptoms, medication use and the activity of bone absorption markers. It has been known that antipsychotic-induced hyperprolactinemia plays a critical role on decreased BMD. However, it remains uncertain whether the risk factors differ between men and women...
August 31, 2016: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27487259/effects-of-switching-to-aripiprazole-from-current-atypical-antipsychotics-on-subsyndromal-symptoms-and-tolerability-in-patients-with-bipolar-disorder
#19
Young Sup Woo, Won-Myong Bahk, Young-Min Park, Sangkeun Chung, Bo-Hyun Yoon, Seunghee Won, Jeong Goo Lee, Hwang-Bin Lee, Won Kim, Jong-Hyun Jeong, Kwanghun Lee, Moon-Doo Kim
We evaluated the effectiveness of aripiprazole among bipolar patients who had switched to this medication as a result of difficulty maintaining on their prestudy atypical antipsychotics (AAPs) because of subsyndromal mood symptoms or intolerance. This study included 77 bipolar patients who were in syndromal remission with an AAP as monotherapy or with an AAP combined with a mood stabilizer(s) who needed to switch from their present AAP because of subsyndromal symptoms or intolerance. At 24 weeks after switching to aripiprazole, the remission rates on the Montgomery-Åsberg Depression Rating Scale (MADRS) and on both the MADRS and the Young Mania Rating Scale were increased significantly in the full sample and in the inefficacy subgroup...
September 2016: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27440212/cariprazine-for-the-treatment-of-schizophrenia-a-review-of-this-dopamine-d3-preferring-d3-d2-receptor-partial-agonist
#20
REVIEW
Leslie Citrome
Cariprazine is an antipsychotic medication and received approval by the U.S. Food and Drug Administration for the treatment of schizophrenia in September 2015. Cariprazine is a dopamine D3 and D2 receptor partial agonist, with a preference for the D3 receptor. Cariprazine is also a partial agonist at the serotonin 5-HT1A receptor and acts as an antagonist at 5-HT2B and 5-HT2A receptors. The recommended dose range of cariprazine for the treatment of schizophrenia is 1.5-6 mg/d; the starting dose of 1.5 mg/d is potentially therapeutic...
2016: Clinical Schizophrenia & related Psychoses
keyword
keyword
51269
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"